| Patient | Wilma Rudolph |
|---|---|
| Date of birth | 1972-06-23 |
| Identifiers | MRN HR-ML036-SYN; SSN (made up) 000-36-5170 |
| Document date | 2026-11-01 |
| Author | Gloria Haynes-Whitaker, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
New headaches, word-finding pauses and right-hand clumsiness in a woman of 54: neurologic examination, MRI of the brain booked for the next morning, and neuro-oncology review booked. Concerns: Headaches on waking for three weeks, now most mornings; words that will not come for ten days; dropping things from the right hand; She wants the cause found quickly and explained plainly, without being talked around; She worries about falling and about losing her independence: her left leg was the weak one when she was a child, and now her right hand is clumsy. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a day | Two tablets every 6 hours as needed | Oral route | 2026-06-29 | active | S |
| Dexamethasone 4 mg oral tablet, one tablet twice a day with food, for symptomatic vasogenic edema, until surgery | One tablet twice a day with breakfast and lunch | Oral route | 2026-06-30 to 2026-07-08 | completed | S |
| Famotidine 20 mg oral tablet, one tablet twice a day while taking dexamethasone | One tablet twice a day | Oral route | 2026-06-30 to 2026-08-12 | completed | S |
| Dexamethasone 2 mg oral tablet, one tablet twice a day after surgery, tapering | One tablet twice a day | Oral route | 2026-07-10 to 2026-07-29 | completed | S |
| Dexamethasone 2 mg oral tablet: one tablet daily for one week, then half a tablet daily for one week, then stop | One tablet daily for a week, then half a tablet daily for a week | Oral route | 2026-07-29 to 2026-08-12 | completed | S |
| Temozolomide 140 mg oral capsule, 140 mg (75 mg/m2) by mouth daily at bedtime on an empty stomach, seven days a week for 42 days from the first day of radiotherapy | Once daily at bedtime, seven days a week, for 42 days | Oral route | 2026-08-03 to 2026-09-13 | completed | S |
| Sulfamethoxazole 800 mg and trimethoprim 160 mg oral tablet, one tablet three times a week (Monday, Wednesday and Friday) to prevent Pneumocystis pneumonia | One tablet on Monday, Wednesday and Friday | Oral route | 2026-08-03 | active | S |
| Ondansetron 8 mg oral tablet, one tablet 30 to 60 minutes before each temozolomide dose, and every 8 hours as needed for nausea | Before each temozolomide dose; every 8 hours as needed | Oral route | 2026-08-03 | active | S |
| Temozolomide 140 mg oral capsule, 280 mg (150 mg/m2) by mouth at bedtime on days 1 to 5 of each 28-day cycle, adjuvant cycle 1 of 6 | Two capsules once daily at bedtime on days 1 to 5 of each 28-day cycle | Oral route | 2026-10-09 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| MRI of the brain with and without contrast, with diffusion and perfusion: a 3.8 x 3.2 cm ring-enhancing mass in the left posterior frontal lobe, involving the posterior inferior frontal gyrus and abutting the precentral gyrus, with central necrosis, raised relative cerebral blood volume in the enhancing rim, no restricted diffusion in the necrotic center, surrounding FLAIR signal from edema, and 5 mm rightward midline shift; no other lesion | 2026-06-30 to 2026-06-30 | completed | S |
| CT of the chest, abdomen and pelvis with contrast to look for a primary cancer elsewhere: no mass, enlarged lymph node or other lesion | 2026-07-01 to 2026-07-01 | completed | S |
| Functional MRI with diffusion tensor tractography for surgical planning: left-hemisphere language dominance; expressive language activation just in front of the mass; the corticospinal tract displaced but intact | 2026-07-06 to 2026-07-06 | completed | S |
| Awake left frontal craniotomy with cortical and subcortical language and motor mapping and fluorescence-guided resection: gross total resection of the enhancing tumor, stopped at the mapped language sites. Pathology: glioblastoma, IDH-wildtype, CNS WHO grade 4 (necrosis and microvascular proliferation; IDH1 R132H immunostain negative and no IDH1 or IDH2 mutation on sequencing; ATRX retained; TERT promoter mutation; EGFR amplification; gain of chromosome 7 and loss of chromosome 10; CDKN2A homozygous deletion; histone H3 and BRAF wild-type). MGMT promoter methylated by pyrosequencing. Inpatient stay of three days, with mechanical and then low-molecular-weight heparin prophylaxis against venous thromboembolism from the day after surgery | 2026-07-08 to 2026-07-08 | completed | S |
| MRI of the brain with and without contrast within 48 hours of surgery: no residual enhancing tumor; expected postoperative blood products; small area of restricted diffusion at the posterior margin from surgery; edema and midline shift less | 2026-07-09 to 2026-07-09 | completed | S |
| Outpatient physical therapy assessment: mild weakness of the right hand and hip flexors after surgery; the left calf, weakened by polio in childhood, slightly smaller than the right with full strength; Timed Up and Go 9 seconds; home exercise program, home safety review and a fall plan | 2026-07-22 to 2026-07-22 | completed | S |
| External beam radiotherapy to the resection cavity and margin, 60 Gy in 30 daily fractions over six weeks, with daily temozolomide; given in full on schedule | 2026-08-03 to 2026-09-11 | completed | S |
| Outpatient palliative care consultation alongside cancer treatment: symptoms, coping, her understanding of the illness, goals and wishes, support for her family, and advance care planning; she named a health care agent (recorded in the confidential part of the chart) and completed an advance directive | 2026-09-28 to 2026-09-28 | completed | S |
| MRI of the brain with and without contrast four weeks after chemoradiation: thin, smooth enhancement along the resection cavity with no nodular or new enhancement; FLAIR change around the cavity slightly less than after surgery; no new lesion. Treatment-related change; no progression (RANO 2.0); this scan is the new baseline | 2026-10-07 to 2026-10-07 | completed | S |
| Advance care planning conversation, about 20 minutes, reviewing the advance directive completed with palliative care | 2026-10-29 to 2026-10-29 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2026-10-29 | Influenza vaccine, inactivated, trivalent, preservative free, this season | completed | S |
| 2026-10-29 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 2026-10-29 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| June 23, 1940 | Born prematurely, weighing about 4.5 pounds | D (CLM-0002) |
| about 1944 | Double pneumonia followed by scarlet fever at about age four, among other childhood illnesses | D (CLM-0003) |
| about 1945 | Poliomyelitis in early childhood, leaving the left leg paralyzed or partly paralyzed, with the foot turned inward | D (CLM-0004) |
| about 1946 | Metal leg brace and special shoe for several years; weekly treatment at Meharry Medical College in Nashville, with massage and heat, and massage at home several times a day | D (CLM-0005) |
| about 1952 | Walking without the brace by about age 12; later an Olympic sprinter | D (CLM-0006, CLM-0007) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| Headaches on waking for three weeks, now most mornings; words that will not come for ten days; dropping things from the right hand | active | S |
| She wants the cause found quickly and explained plainly, without being talked around | active | S |
| She worries about falling and about losing her independence: her left leg was the weak one when she was a child, and now her right hand is clumsy | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 11.8 on 2026-10-29; Leukocytes [#/volume] in Blood by Automated count 3.4 on 2026-10-29; Platelets [#/volume] in Blood by Automated count 121 on 2026-10-29; Sodium [Moles/volume] in Serum or Plasma 140 on 2026-07-02; Potassium [Moles/volume] in Serum or Plasma 4 on 2026-07-02; Creatinine [Mass/volume] in Serum or Plasma 0.81 on 2026-10-09; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 86 on 2026-10-09; Glucose [Mass/volume] in Serum or Plasma 91 on 2026-10-09; Hemoglobin A1c/Hemoglobin.total in Blood 5.6 on 2026-06-29; Karnofsky Performance Status score 80 on 2026-10-09; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 2026-10-29; INR in Platelet poor plasma by Coagulation assay 1 on 2026-07-02; aPTT in Blood by Coagulation assay 29 on 2026-07-02; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 6 on 2026-10-09; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 9 on 2026-07-02; Neutrophils [#/volume] in Blood by Automated count 1.9 on 2026-10-29; Lymphocytes [#/volume] in Blood by Automated count 0.6 on 2026-10-29; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 33 on 2026-10-29; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 29 on 2026-10-29; Bilirubin.total [Mass/volume] in Serum or Plasma 0.5 on 2026-10-09; Albumin [Mass/volume] in Serum or Plasma 4 on 2026-07-29 [S]
Strengths and supports: Vice president of a Nashville hospital; former Olympic champion sprinter, teacher and coach; runs a foundation that supports young track and field athletes [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Three weeks of headaches on waking, with ten days of pauses in finding words and clumsiness of the right hand, in a previously well woman of 54: an intracranial lesion must be excluded. MRI of the brain with and without contrast booked for tomorrow morning, and neuro-oncology review booked | resolved | confirmed | R29.818 | S — Synthetic presenting problem; no symptom of her real illness was made public. Superseded when the MRI showed a brain mass. |
| Left posterior frontal ring-enhancing mass, 3.8 cm, with central necrosis, surrounding edema and 5 mm midline shift, next to the language and motor areas; presumed high-grade glioma, with no primary cancer elsewhere on CT; tissue diagnosis pending | resolved | confirmed | D49.6 | S — Synthetic imaging diagnosis before surgery; superseded by the pathology. |
| Glioblastoma, IDH-wildtype, CNS WHO grade 4, left posterior frontal lobe, MGMT promoter methylated, after gross total resection of the enhancing tumor; synthetic modern detail linked to her publicly reported brain cancer | active | confirmed | C71.1 | S — Synthetic histology, molecular result and location; brain cancer is documented as the cause of her death (D), and nothing more about it was made public. |
| Late effects of childhood poliomyelitis: paralysis of the left leg in early childhood, treated with a metal brace, a special shoe, massage and heat, with full recovery of walking by about age 12 and a later career as an Olympic sprinter; no new weakness, fatigue or pain now to suggest post-polio syndrome | active | confirmed | B91 | S — Documented childhood polio (D); the current absence of new symptoms is synthetic. |
| Vasogenic cerebral edema around the left frontal mass, with 5 mm midline shift, causing headache and contributing to the language and right-hand symptoms; treated with dexamethasone | resolved | confirmed | G93.6 | S — Synthetic finding on the first MRI. |
| Steroid-induced hyperglycemia on dexamethasone: random glucose 168 mg/dL, with an A1c of 5.6% before steroids | resolved | confirmed | R73.9 | S — Synthetic common effect of dexamethasone; resolved after the taper. |
| Lymphopenia from temozolomide, grade 2 (absolute lymphocytes 0.5 x 10^3/uL at the end of chemoradiation): Pneumocystis prophylaxis continues until recovery to grade 1 or better | active | confirmed | D72.810 | S — Synthetic common effect of daily temozolomide with radiotherapy. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-29 | Hemoglobin [Mass/volume] in Blood | 13.1 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-06-29 | Leukocytes [#/volume] in Blood by Automated count | 7.1 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-06-29 | Platelets [#/volume] in Blood by Automated count | 262 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-06-29 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-06-29 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-06-29 | Creatinine [Mass/volume] in Serum or Plasma | 0.86 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-06-29 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 80 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-06-29 | Glucose [Mass/volume] in Serum or Plasma | 92 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-06-29 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.6 | % | Below 5.7% is normal; 5.7 to 6.4% prediabetes | Normal | S |
| 2026-06-29 | Karnofsky Performance Status score | 80 | {score} | S | ||
| 2026-06-29 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2026-07-02 | Hemoglobin [Mass/volume] in Blood | 13 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-07-02 | Leukocytes [#/volume] in Blood by Automated count | 11.8 | 10*3/uL | 4-11 10*3/uL | High | S |
| 2026-07-02 | Platelets [#/volume] in Blood by Automated count | 270 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-07-02 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-07-02 | Potassium [Moles/volume] in Serum or Plasma | 4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-07-02 | Creatinine [Mass/volume] in Serum or Plasma | 0.84 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-07-02 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 83 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-07-02 | Glucose [Mass/volume] in Serum or Plasma | 138 | mg/dL | 70-99 mg/dL | High | S |
| 2026-07-02 | INR in Platelet poor plasma by Coagulation assay | 1 | {INR} | 0.9-1.1 | Normal | S |
| 2026-07-02 | aPTT in Blood by Coagulation assay | 29 | s | 25-37 s | Normal | S |
| 2026-07-02 | Karnofsky Performance Status score | 80 | {score} | S | ||
| 2026-07-02 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 2026-07-02 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 9 | {score} | S | ||
| 2026-07-29 | Hemoglobin [Mass/volume] in Blood | 12.6 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-07-29 | Leukocytes [#/volume] in Blood by Automated count | 9.6 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-07-29 | Neutrophils [#/volume] in Blood by Automated count | 7.2 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 2026-07-29 | Lymphocytes [#/volume] in Blood by Automated count | 1.1 | 10*3/uL | 1-4 10*3/uL | Normal | S |
| 2026-07-29 | Platelets [#/volume] in Blood by Automated count | 248 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-07-29 | Creatinine [Mass/volume] in Serum or Plasma | 0.82 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-07-29 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 85 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-07-29 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 | U/L | 7-35 U/L | Normal | S |
| 2026-07-29 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 8-35 U/L | Normal | S |
| 2026-07-29 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-07-29 | Albumin [Mass/volume] in Serum or Plasma | 4 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-07-29 | Glucose [Mass/volume] in Serum or Plasma | 168 | mg/dL | 70-99 mg/dL | High | S |
| 2026-07-29 | Karnofsky Performance Status score | 90 | {score} | S | ||
| 2026-07-29 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 2026-09-14 | Hemoglobin [Mass/volume] in Blood | 11.9 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-09-14 | Leukocytes [#/volume] in Blood by Automated count | 3.6 | 10*3/uL | 4-11 10*3/uL | Low | S |
| 2026-09-14 | Neutrophils [#/volume] in Blood by Automated count | 2.4 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 2026-09-14 | Lymphocytes [#/volume] in Blood by Automated count | 0.5 | 10*3/uL | 1-4 10*3/uL | Low | S |
| 2026-09-14 | Platelets [#/volume] in Blood by Automated count | 112 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 2026-09-14 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-09-14 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 88 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-09-14 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 48 | U/L | 7-35 U/L | High | S |
| 2026-09-14 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 39 | U/L | 8-35 U/L | High | S |
| 2026-09-14 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-09-14 | Glucose [Mass/volume] in Serum or Plasma | 96 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-09-14 | Karnofsky Performance Status score | 80 | {score} | S | ||
| 2026-09-14 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | {score} | S | ||
| 2026-10-09 | Hemoglobin [Mass/volume] in Blood | 12.2 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-10-09 | Leukocytes [#/volume] in Blood by Automated count | 4.4 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-10-09 | Neutrophils [#/volume] in Blood by Automated count | 2.9 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 2026-10-09 | Lymphocytes [#/volume] in Blood by Automated count | 0.6 | 10*3/uL | 1-4 10*3/uL | Low | S |
| 2026-10-09 | Platelets [#/volume] in Blood by Automated count | 168 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-10-09 | Creatinine [Mass/volume] in Serum or Plasma | 0.81 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-10-09 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 86 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-10-09 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 | U/L | 7-35 U/L | Normal | S |
| 2026-10-09 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 | U/L | 8-35 U/L | Normal | S |
| 2026-10-09 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-10-09 | Glucose [Mass/volume] in Serum or Plasma | 91 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-10-09 | Karnofsky Performance Status score | 80 | {score} | S | ||
| 2026-10-09 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 2026-10-29 | Hemoglobin [Mass/volume] in Blood | 11.8 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-10-29 | Leukocytes [#/volume] in Blood by Automated count | 3.4 | 10*3/uL | 4-11 10*3/uL | Low | S |
| 2026-10-29 | Neutrophils [#/volume] in Blood by Automated count | 1.9 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 2026-10-29 | Lymphocytes [#/volume] in Blood by Automated count | 0.6 | 10*3/uL | 1-4 10*3/uL | Low | S |
| 2026-10-29 | Platelets [#/volume] in Blood by Automated count | 121 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 2026-10-29 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 33 | U/L | 7-35 U/L | Normal | S |
| 2026-10-29 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 29 | U/L | 8-35 U/L | Normal | S |
| 2026-10-29 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-29 | Body height | 180 | cm | S |
| 2026-06-29 | Body weight | 68 | kg | S |
| 2026-06-29 | Body mass index (BMI) [Ratio] | 21 | kg/m2 | S |
| 2026-06-29 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-06-29 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-06-29 | Heart rate | 72 | /min | S |
| 2026-06-29 | Respiratory rate | 14 | /min | S |
| 2026-06-29 | Body temperature | 36.7 | Cel | S |
| 2026-06-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-07-02 | Body height | 180 | cm | S |
| 2026-07-02 | Body weight | 67.8 | kg | S |
| 2026-07-02 | Body mass index (BMI) [Ratio] | 20.9 | kg/m2 | S |
| 2026-07-02 | Systolic blood pressure | 134 | mm[Hg] | S |
| 2026-07-02 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 2026-07-02 | Heart rate | 78 | /min | S |
| 2026-07-02 | Respiratory rate | 14 | /min | S |
| 2026-07-02 | Body temperature | 36.6 | Cel | S |
| 2026-07-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-07-29 | Body height | 180 | cm | S |
| 2026-07-29 | Body weight | 69.4 | kg | S |
| 2026-07-29 | Body mass index (BMI) [Ratio] | 21.4 | kg/m2 | S |
| 2026-07-29 | Systolic blood pressure | 132 | mm[Hg] | S |
| 2026-07-29 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-07-29 | Heart rate | 76 | /min | S |
| 2026-07-29 | Respiratory rate | 14 | /min | S |
| 2026-07-29 | Body temperature | 36.6 | Cel | S |
| 2026-07-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-09-14 | Body height | 180 | cm | S |
| 2026-09-14 | Body weight | 67.2 | kg | S |
| 2026-09-14 | Body mass index (BMI) [Ratio] | 20.7 | kg/m2 | S |
| 2026-09-14 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-09-14 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-09-14 | Heart rate | 80 | /min | S |
| 2026-09-14 | Respiratory rate | 16 | /min | S |
| 2026-09-14 | Body temperature | 36.8 | Cel | S |
| 2026-09-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-10-09 | Body height | 180 | cm | S |
| 2026-10-09 | Body weight | 66.6 | kg | S |
| 2026-10-09 | Body mass index (BMI) [Ratio] | 20.6 | kg/m2 | S |
| 2026-10-09 | Systolic blood pressure | 120 | mm[Hg] | S |
| 2026-10-09 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-10-09 | Heart rate | 74 | /min | S |
| 2026-10-09 | Respiratory rate | 14 | /min | S |
| 2026-10-09 | Body temperature | 36.6 | Cel | S |
| 2026-10-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-10-29 | Body height | 180 | cm | S |
| 2026-10-29 | Body weight | 66.9 | kg | S |
| 2026-10-29 | Body mass index (BMI) [Ratio] | 20.6 | kg/m2 | S |
| 2026-10-29 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-10-29 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-10-29 | Heart rate | 76 | /min | S |
| 2026-10-29 | Respiratory rate | 14 | /min | S |
| 2026-10-29 | Body temperature | 36.5 | Cel | S |
| 2026-10-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-06-29 | New headaches, word-finding pauses and right-hand clumsiness in a woman of 54: neurologic examination, MRI of the brain booked for the next morning, and neuro-oncology review booked | finished | S |
| 2026-07-02 | MRI result: left frontal mass with edema; dexamethasone, CT staging, neuro-oncology consultation with neurosurgery, and preparation for awake craniotomy | finished | S |
| 2026-07-29 | Review three weeks after awake craniotomy: pathology and molecular diagnosis, steroid taper, steroid-related hyperglycemia, falls, and the plan for radiotherapy with temozolomide | finished | S |
| 2026-09-14 | End of six weeks of radiotherapy with daily temozolomide: blood counts, liver tests, Pneumocystis prophylaxis, fatigue, mood, tumor-treating fields and an early palliative care referral | finished | S |
| 2026-10-09 | Post-chemoradiation MRI result, day 1 of adjuvant temozolomide, the start of tumor-treating fields, and the palliative care plan | finished | S |
| 2026-10-29 | Periodic adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Urgent neuro-oncology consultation within one week, together with neurosurgery, to review the brain MRI with her and plan diagnosis and treatment if it shows a tumor | completed | GL-NCCN-CNS-2026, GL-EANO-GLIOMA-2021 | S |
| New progressive focal neurologic symptoms are imaged promptly: MRI of the brain with and without contrast within 24 hours, with same-day emergency care if she worsens, has a seizure, vomits or becomes drowsy; blood count, chemistry and A1c; no driving until the cause is known | completed | GL-NCCN-CNS-2026, GL-EANO-GLIOMA-2021 | S |
| Dexamethasone only for edema causing symptoms, at the lowest effective dose (4 mg twice a day), with famotidine and glucose checks, and tapered off as soon as possible after surgery | completed | GL-EANO-GLIOMA-2021, GL-NCCN-CNS-2026 | S |
| CT of the chest, abdomen and pelvis to exclude another primary; functional MRI with tractography; awake craniotomy with language and motor mapping for maximal safe resection; MRI within 48 hours; integrated WHO CNS5 diagnosis with IDH1 R132H immunostaining and IDH1 and IDH2 sequencing, ATRX, TERT promoter, EGFR, chromosome 7 and 10, CDKN2A, histone H3, BRAF and MGMT promoter methylation | completed | GL-NCCN-CNS-2026, GL-EANO-GLIOMA-2021, GL-WHO-CNS5-2021 | S |
| No antiseizure prophylaxis, because she has had no seizure; seizure first aid taught to her and her household; levetiracetam if a seizure occurs | completed | GL-SNO-EANO-AED-2021, GL-EANO-GLIOMA-2021 | S |
| Venous thromboembolism: mechanical and then low-molecular-weight heparin prophylaxis in hospital after surgery; no routine prophylaxis at home; she is taught the signs of leg clot and pulmonary embolism and to report them the same day | completed | GL-ASCO-VTE-2023, GL-NCCN-CNS-2026 | S |
| Radiotherapy 60 Gy in 30 fractions with temozolomide 75 mg/m2 daily, then six cycles of temozolomide 150 to 200 mg/m2 on days 1 to 5 of each 28-day cycle; Pneumocystis prophylaxis during concurrent treatment and while lymphopenia lasts; antiemetic before each dose; blood count weekly during chemoradiation and on day 22 of each adjuvant cycle; liver tests at baseline, mid-cycle 1 and before each cycle; MRI four weeks after radiotherapy and then every two to three months, read by RANO 2.0; clinical trial screening | completed | GL-NCCN-CNS-2026, GL-EANO-GLIOMA-2021, GL-STUPP-2005, GL-HEGI-2005, GL-TMZ-LABEL, GL-ASCO-SNO-2022, GL-RANO-2023 | S |
| Tumor-treating fields with adjuvant temozolomide, worn at least 18 hours a day, with scalp checks and skin care | completed | GL-EF14-2017, GL-NCCN-CNS-2026, GL-EANO-GLIOMA-2021 | S |
| Falls and mobility from the first visit: home safety review, fall plan, physical therapy assessment once the treatment plan is set, and a check at every visit of strength in both legs, since new right-sided weakness adds to a left leg weakened by polio in childhood; watch for new weakness, fatigue or pain that could signal post-polio syndrome | completed | GL-EFNS-PPS-2006, GL-EANO-GLIOMA-2021 | S |
| Early palliative care alongside cancer treatment: symptoms, coping, goals and advance care planning, and support for the people she chooses | completed | GL-ASCO-PALL-2024, GL-NCCN-CNS-2026, GL-EANO-GLIOMA-2021 | S |
| Distress and depression screening at each visit, plain explanations with written information, and help to keep working as long as she wishes; she decides who receives information | completed | GL-USPSTF-DEP-2023, GL-CMID-2026, GL-NCCN-CNS-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| MRI of the brain within 24 hours and a neuro-oncology and neurosurgery plan within one week of presentation | 2026-07-02 | completed | MRI the next morning; consultation three days after the first visit | S |
| Maximal safe resection within two weeks of the MRI, preserving language and right-hand strength | 2026-07-29 | completed | Gross total resection of the enhancing tumor nine days after the first visit; speech back to normal within days and right-hand strength nearly normal | S |
| Radiotherapy with daily temozolomide started within six weeks of surgery and completed on schedule | 2026-09-14 | completed | Started 26 days after surgery; 30 fractions and 42 days of temozolomide completed without a break | S |
| Dexamethasone tapered off within five weeks of surgery, with glucose back to normal | 2026-09-14 | completed | Off dexamethasone five weeks after surgery; glucose 96 mg/dL afterwards | S |
| No falls, and walking independently, through treatment | 2026-10-09 | completed | No falls; walks independently, with a cane only on uneven ground; home exercise program continued | S |
| Palliative care involved and her wishes recorded before adjuvant treatment begins | 2026-10-09 | completed | Palliative care consultation and advance directive completed eleven days before adjuvant cycle 1 | S |